Literature DB >> 22094131

Modelling of Parkinson's disease in mice.

Marie-Françoise Chesselet1, Franziska Richter.   

Abstract

Although progress has been made in the symptomatic treatment of Parkinson's disease since the discovery of L-dopa in the 1960s, no neuroprotective therapy is yet available. Absence of adequate animal models of the disease that enable prediction of clinical success of potential treatments is often cited as a major impediment to progress and discourages researchers and pharmaceutical companies from investing resources to develop such treatments. Classic models are still widely used, but have been disappointing, and development of genetic models has given new hope. However, can a human disease be faithfully reproduced in a mouse? In this Review we summarise evidence that some genetic mouse models do reproduce key features of Parkinson's disease and show that much can be learned from even imperfect models. The hope is that this information could be used to advance the search for neuroprotective therapies for Parkinson's disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094131     DOI: 10.1016/S1474-4422(11)70227-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  81 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Animal models of neurological disorders.

Authors:  Marie-Francoise Chesselet; S Thomas Carmichael
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 3.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

4.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

5.  Decreased approach behavior and nucleus accumbens immediate early gene expression in response to Parkinsonian ultrasonic vocalizations in rats.

Authors:  Joshua D Pultorak; Cynthia A Kelm-Nelson; Lauren R Holt; Katherine V Blue; Michelle R Ciucci; Aaron M Johnson
Journal:  Soc Neurosci       Date:  2015-09-14       Impact factor: 2.083

6.  Synj1 haploinsufficiency causes dopamine neuron vulnerability and alpha-synuclein accumulation in mice.

Authors:  Ping-Yue Pan; Patricia Sheehan; Qian Wang; Xinyu Zhu; Yuanxi Zhang; Insup Choi; Xianting Li; Jacqueline Saenz; Justin Zhu; Jing Wang; Farida El Gaamouch; Li Zhu; Dongming Cai; Zhenyu Yue
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

7.  Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease.

Authors:  Saurav Brahmachari; Saebom Lee; Sangjune Kim; Changqing Yuan; Senthilkumar S Karuppagounder; Preston Ge; Rosa Shi; Esther J Kim; Alex Liu; Donghoon Kim; Stephan Quintin; Haisong Jiang; Manoj Kumar; Seung Pil Yun; Tae-In Kam; Xiaobo Mao; Yunjong Lee; Deborah A Swing; Lino Tessarollo; Han Seok Ko; Valina L Dawson; Ted M Dawson
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

8.  Mitochondrial permeability transition pore regulates Parkinson's disease development in mutant α-synuclein transgenic mice.

Authors:  Lee J Martin; Samantha Semenkow; Allison Hanaford; Margaret Wong
Journal:  Neurobiol Aging       Date:  2013-11-16       Impact factor: 4.673

9.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

10.  Vocalization deficits in mice over-expressing alpha-synuclein, a model of pre-manifest Parkinson's disease.

Authors:  Laura M Grant; Franziska Richter; Julie E Miller; Stephanie A White; Cynthia M Fox; Chunni Zhu; Marie-Francoise Chesselet; Michelle R Ciucci
Journal:  Behav Neurosci       Date:  2014-04       Impact factor: 1.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.